Sulfapyridine

CHEMBL700 Phase 4 승인됨 Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
249.3 g/mol
LogP
Phase
4

Sulfapyridine is a sulfonamide antibacterial used as an active metabolite of sulfasalazine and independently for the treatment of dermatitis herpetiformis and linear IgA bullous dermatosis, where it suppresses neutrophil-mediated cutaneous inflammation. Sulfasalazine is cleaved in the colon by bacteria to release mesalazine (anti-inflammatory) and sulfapyridine, the carrier that ensures colonic delivery. In dermatitis herpetiformis, its anti-inflammatory mechanism likely involves suppression of neutrophil chemotaxis and oxidative burst.

분자량

249.2900 g/mol

LogP

0.00

TPSA

93.50 Ų

리핀스키 5의 법칙

통과

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D 구조

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Nc1ccc(S(=O)(=O)Nc2ccccn2)cc1

InChI

InChI=1S/C11H11N3O2S/c12-9-4-6-10(7-5-9)17(15,16)14-11-3-1-2-8-13-11/h1-8H,12H2,(H,13,14)

Molecular Formula

C11H11N3O2S

HBD / HBA

2 / 5

회전 가능 결합

3

무거운 원자

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

Sulfapyridine is a sulfonamide antibacterial used as an active metabolite of sulfasalazine and independently for the treatment of dermatitis herpetiformis and linear IgA bullous dermatosis, where it suppresses neutrophil-mediated cutaneous inflammation. Sulfasalazine is cleaved in the colon by bacteria to release mesalazine (anti-inflammatory) and sulfapyridine, the carrier that ensures colonic delivery. In dermatitis herpetiformis, its anti-inflammatory mechanism likely involves suppression of neutrophil chemotaxis and oxidative burst.

Yes, Sulfapyridine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL700. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5336. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.